← Back to Search

Immunomodulator

Orencia (Abatacept) for Sjogren's Syndrome

Phase 2
Waitlist Available
Research Sponsored by Arthritis & Rheumatism Associates, P.C.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects diagnosed with Sjogren's Syndrome
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 32 weeks
Awards & highlights

Study Summary

This trial looked at how well the salivary glands work in people with Sjogren's syndrome.

Eligible Conditions
  • Sjogren's Syndrome

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Salivary gland changes

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Orencia (Abatacept)Active Control1 Intervention
Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
Group II: PlaceboPlacebo Group1 Intervention
Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)

Find a Location

Who is running the clinical trial?

Arthritis & Rheumatism Associates, P.C.Lead Sponsor
2 Previous Clinical Trials
300 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,629 Previous Clinical Trials
4,126,516 Total Patients Enrolled
8 Trials studying Sjogren's Syndrome
1,626 Patients Enrolled for Sjogren's Syndrome

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025